These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
602 related articles for article (PubMed ID: 21149657)
1. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657 [TBL] [Abstract][Full Text] [Related]
2. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745 [TBL] [Abstract][Full Text] [Related]
3. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611 [TBL] [Abstract][Full Text] [Related]
5. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Okada H; Butterfield LH; Hamilton RL; Hoji A; Sakaki M; Ahn BJ; Kohanbash G; Drappatz J; Engh J; Amankulor N; Lively MO; Chan MD; Salazar AM; Shaw EG; Potter DM; Lieberman FS Clin Cancer Res; 2015 Jan; 21(2):286-94. PubMed ID: 25424847 [TBL] [Abstract][Full Text] [Related]
6. Brain tumor immunotherapy with type-1 polarizing strategies. Okada H Ann N Y Acad Sci; 2009 Sep; 1174():18-23. PubMed ID: 19769732 [TBL] [Abstract][Full Text] [Related]
7. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916 [TBL] [Abstract][Full Text] [Related]
8. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Ishikawa T; Kageyama S; Miyahara Y; Okayama T; Kokura S; Wang L; Sato E; Yagita H; Itoh Y; Shiku H Cancer Immunol Immunother; 2021 Nov; 70(11):3081-3091. PubMed ID: 33751208 [TBL] [Abstract][Full Text] [Related]
9. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H J Neurooncol; 2016 Dec; 130(3):517-527. PubMed ID: 27624914 [TBL] [Abstract][Full Text] [Related]
10. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Butowski N; Lamborn KR; Lee BL; Prados MD; Cloughesy T; DeAngelis LM; Abrey L; Fink K; Lieberman F; Mehta M; Ian Robins H; Junck L; Salazar AM; Chang SM J Neurooncol; 2009 Jan; 91(2):183-9. PubMed ID: 18850068 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745 [TBL] [Abstract][Full Text] [Related]
12. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206 [TBL] [Abstract][Full Text] [Related]
13. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Mehrotra S; Britten CD; Chin S; Garrett-Mayer E; Cloud CA; Li M; Scurti G; Salem ML; Nelson MH; Thomas MB; Paulos CM; Salazar AM; Nishimura MI; Rubinstein MP; Li Z; Cole DJ J Hematol Oncol; 2017 Apr; 10(1):82. PubMed ID: 28388966 [TBL] [Abstract][Full Text] [Related]
14. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Butowski N; Chang SM; Junck L; DeAngelis LM; Abrey L; Fink K; Cloughesy T; Lamborn KR; Salazar AM; Prados MD J Neurooncol; 2009 Jan; 91(2):175-82. PubMed ID: 18797818 [TBL] [Abstract][Full Text] [Related]
15. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709 [TBL] [Abstract][Full Text] [Related]
16. A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. Dillon PM; Petroni GR; Smolkin ME; Brenin DR; Chianese-Bullock KA; Smith KT; Olson WC; Fanous IS; Nail CJ; Brenin CM; Hall EH; Slingluff CL J Immunother Cancer; 2017 Nov; 5(1):92. PubMed ID: 29157306 [TBL] [Abstract][Full Text] [Related]
17. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Salazar AM; Erlich RB; Mark A; Bhardwaj N; Herberman RB Cancer Immunol Res; 2014 Aug; 2(8):720-4. PubMed ID: 24801836 [TBL] [Abstract][Full Text] [Related]
20. Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Ewel CH; Urba WJ; Kopp WC; Smith JW; Steis RG; Rossio JL; Longo DL; Jones MJ; Alvord WG; Pinsky CM Cancer Res; 1992 Jun; 52(11):3005-10. PubMed ID: 1591717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]